New hope for Hard-to-Treat cancers? early trial launches
NCT ID NCT07160725
First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 3 times
Summary
This early-phase trial is testing a new drug called BMS-986517 in about 315 adults with advanced solid tumors that have spread or cannot be removed by surgery. The main goal is to check the drug's safety and find the right dose. Researchers will also look for signs that the drug shrinks tumors. This is a first-in-human study, so the drug's effects are not yet known.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BMS-986517
- What this could lead to
- If successful, this could point toward a new treatment option for certain advanced solid tumors that have not responded to other therapies.
- What could go wrong
- This is a very early, first-in-human study focused mainly on safety. It is small and may not show enough benefit to move forward. Side effects are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinica Universidad de Navarra
RECRUITINGPamplona, Navarre, 31008, Spain
-
Copenhagen University Hospital Rigshospitalet
RECRUITINGCopenhagen, 2100, Denmark
-
Fred Hutchinson Cancer Center
RECRUITINGSeattle, Washington, 98109, United States
-
Herlev and Gentofte Hospital
RECRUITINGCopenhagen, Capital Region, 2730, Denmark
-
Hospital Universitario Fundación Jiménez Díaz
RECRUITINGMadrid, 28040, Spain
-
Local Institution - 0022
NOT_YET_RECRUITINGBadalona, Barcelona [Barcelona], 08916, Spain
-
Local Institution - 0023
NOT_YET_RECRUITINGMadrid, 28050, Spain
-
Local Institution - 0024
NOT_YET_RECRUITINGBarcelona, Barcelona [Barcelona], 08035, Spain
-
Local Institution - 0026
NOT_YET_RECRUITINGMálaga, Andalusia, 29010, Spain
-
Local Institution - 0033
NOT_YET_RECRUITINGIrvine, California, 92612, United States
-
Local Institution - 0034
NOT_YET_RECRUITINGGuangzhou, Guangdong, 510120, China
-
National Cancer Center Hospital
RECRUITINGChuo-ku, Tokyo, 104-0045, Japan
-
Odense Universitetshospital
RECRUITINGOdense, Region Syddanmark, 5000, Denmark
-
START - Dallas Fort Worth
RECRUITINGFort Worth, Texas, 76104, United States
-
START Mountain Region
RECRUITINGWest Valley City, Utah, 84119, United States
-
START San Antonio
RECRUITINGSan Antonio, Texas, 78229, United States
Contact Email: •••••@•••••
-
Sanford Cancer Center
RECRUITINGSioux Falls, South Dakota, 57104, United States
-
UPMC Hillman Cancer Center
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
-
USC/Norris Comprehensive Cancer Center
RECRUITINGLos Angeles, California, 90033, United States
-
University of California, Irvine (UCI) Health - UC Irvine Medical Center
RECRUITINGOrange, California, 92868-3201, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital peer support: a new weapon against cancer treatment anxiety?
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Can targeted radiation boost Immunotherapy's power against head and neck cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?